Publications by authors named "Stanley Marciniak"

Claim this Profile
S
Safety, tolerability, and efficacy of the PD-1 agonist antibody JNJ-67484703 in adults with active rheumatoid arthritis: results of a multicenter, double-blind, placebo-controlled, randomized, multiple-dose phase Ib study.
Irving T C Ling, Stanley J Marciniak, Stephen H Clarke, Vani Lakshminarayanan, Matthew J Loza

Ther Adv Musculoskelet Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel signatures associated with systemic lupus erythematosus clinical response to IFN-α/-ω inhibition.
Loqmane Seridi, Matteo Cesaroni, Ashley Orillion, Jessica Schreiter, Marc Chevrier, Stanley Marciniak

Lupus· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus.
Zhenling Yao, Laura Loggia, Damien Fink, Marc Chevrier, Stanley Marciniak

Clin Drug Investig· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human study of JNJ-55920839 in healthy volunteers and patients with systemic lupus erythematosus: a randomised placebo-controlled phase 1 trial.
Jarrat Jordan, Jacqueline Benson, Walter Winn Chatham, Richard Alan Furie, William Stohl, Stanley Marciniak

Lancet Rheumatol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.
Yanli Zhuang, Cesar Calderon, Stanley J Marciniak, Esther Bouman-Thio, Philippe Szapary

Eur J Clin Pharmacol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach.
Yanli Zhuang, Dick E de Vries, Zhenhua Xu, Stanley J Marciniak, Dion Chen

J Clin Pharmacol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic bridging approach for developing biologics-delivery devices: a case study with a golimumab autoinjector.
Zhenhua Xu, Stanley J Marciniak, Bart Frederick, Lilianne Kim, Yanli Zhuang

Clin Ther· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1, randomized study to assess the pharmacokinetic comparability of siltuximab derived from two different cell lines in healthy subjects.
Chao Xu, Chao Han, Joseph Marini, Joyce Ford, Stanley Marciniak

Clin Pharmacol Drug Dev· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
Howard Sofen, Stacy Smith, Robert T Matheson, Craig L Leonardi, Cesar Calderon, Stanley J Marciniak

J Allergy Clin Immunol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects.
Esther Bouman-Thio, Kari Franson, Bruce Miller, John Getsy, Adam Cohen, Stanley Marciniak

J Clin Pharmacol· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.
Honghui Zhou, Haishan Jang, Roy M Fleischmann, Esther Bouman-Thio, Zhenhua Xu, Stanley J Marciniak

J Clin Pharmacol· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates.
Stanley J Marciniak, Mary A Mascelli, Mark I Furman, Alan D Michelson, Joseph A Jakubowski

Thromb Haemost· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced inhibition by abciximab in platelets with the PlA2 polymorphism.
Guy L Wheeler, Gregory A Braden, Paul F Bray, Stanley J Marciniak, Mary Ann Mascelli

Am Heart J· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis